Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea?

Unemo M, Golparian D, Limnios A, Whiley D, Ohnishi M, Lahra MM, Tapsall JW.

Antimicrob Agents Chemother. 2012 Jul;56(7):3603-9. doi: 10.1128/AAC.00326-12. Epub 2012 Apr 30.

2.

Reduced susceptibility to ceftriaxone in Neisseria gonorrhoeae is spread internationally by genetically distinct gonococcal populations.

Whiley DM, Goire N, Lambert SB, Nissen MD, Sloots TP, Tapsall JW.

J Antimicrob Chemother. 2011 May;66(5):1186-7. doi: 10.1093/jac/dkr052. Epub 2011 Feb 24. No abstract available.

PMID:
21393170
3.

Enhancing gonococcal antimicrobial resistance surveillance: a real-time PCR assay for detection of penicillinase-producing Neisseria gonorrhoeae by use of noncultured clinical samples.

Goire N, Freeman K, Tapsall JW, Lambert SB, Nissen MD, Sloots TP, Whiley DM.

J Clin Microbiol. 2011 Feb;49(2):513-8. doi: 10.1128/JCM.02024-10. Epub 2010 Dec 15.

4.

Alterations of the pilQ gene in Neisseria gonorrhoeae are unlikely contributors to decreased susceptibility to ceftriaxone and cefixime in clinical gonococcal strains.

Whiley DM, Jacobsson S, Tapsall JW, Nissen MD, Sloots TP, Unemo M.

J Antimicrob Chemother. 2010 Dec;65(12):2543-7. doi: 10.1093/jac/dkq377. Epub 2010 Oct 12.

PMID:
20940180
5.

Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific and South East Asian regions, 2007-2008.

WHO Western Pacific Programme; South East Asian Gonococcal Antimicrobial Surveillance Programme, Tapsall JW, Limnios EA, Abu Bakar HM, Darussalam B, Ping YY, Buadromo EM, Kumar P, Singh S, Lo J, Bala M, Risbud A, Deguchi T, Tanaka M, Watanabe Y, Lee K, Chong Y, Noikaseumsy S, Phouthavane T, Sam IC, Tundev O, Lwin KM, Eh PH, Goarant C, Goursaud R, Bathgate T, Brokenshire M, Latorre L, Velemu E, Carlos C, Leano S, Telan EO, Goh SS, Koh ST, Ngan C, Tan AL, Mananwatte S, Piyanoot N, Lokpichat S, Sirivongranson P, Fakahau M, Sitanilei H, Hung le V.

Commun Dis Intell Q Rep. 2010 Mar;34(1):1-7.

6.

Reduced susceptibility to ceftriaxone in Neisseria gonorrhoeae is associated with mutations G542S, P551S and P551L in the gonococcal penicillin-binding protein 2.

Whiley DM, Goire N, Lambert SB, Ray S, Limnios EA, Nissen MD, Sloots TP, Tapsall JW.

J Antimicrob Chemother. 2010 Aug;65(8):1615-8. doi: 10.1093/jac/dkq187. Epub 2010 May 28.

PMID:
20511367
7.

Characteristics and population dynamics of mosaic penA allele-containing Neisseria gonorrhoeae isolates collected in Sydney, Australia, in 2007-2008.

Tapsall JW, Ray S, Limnios A.

Antimicrob Agents Chemother. 2010 Jan;54(1):554-6. doi: 10.1128/AAC.01108-09. Epub 2009 Nov 16.

8.

Neisseria gonorrhoeae multi-antigen sequence typing using non-cultured clinical specimens.

Whiley DM, Goire N, Ray ES, Limnios A, Lambert SB, Nissen MD, Sloots TP, Tapsall JW.

Sex Transm Infect. 2010 Feb;86(1):51-5. doi: 10.1136/sti.2009.037689. Epub 2009 Oct 19.

PMID:
19843535
9.

Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae.

Tapsall JW, Ndowa F, Lewis DA, Unemo M.

Expert Rev Anti Infect Ther. 2009 Sep;7(7):821-34. doi: 10.1586/eri.09.63. Review.

PMID:
19735224
10.

Experience with an external quality assurance scheme for antimicrobial susceptibility testing of Neisseria gonorrhoeae in India, 2001-2007.

Bala M, Tapsall JW, Limnios A, Sood S, Ray K.

Epidemiol Infect. 2010 Jan;138(1):69-75. doi: 10.1017/S0950268809990148. Epub 2009 Jun 18.

PMID:
19534842
11.

Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins.

Tapsall JW.

Curr Opin Infect Dis. 2009 Feb;22(1):87-91. doi: 10.1097/QCO.0b013e328320a836. Review.

PMID:
19532086
12.

Simple, rapid, and inexpensive detection of Neisseria gonorrhoeae resistance mechanisms using heat-denatured isolates and SYBR green-based real-time PCR.

Kugelman G, Tapsall JW, Goire N, Syrmis MW, Limnios A, Lambert SB, Nissen MD, Sloots TP, Whiley DM.

Antimicrob Agents Chemother. 2009 Oct;53(10):4211-6. doi: 10.1128/AAC.00385-09. Epub 2009 Jun 15.

13.
14.

Quinolone resistance in Neisseria gonorrhoeae: rapid genotyping of quinolone resistance-determining regions in gyrA and parC genes by melting curve analysis predicts susceptibility.

Vernel-Pauillac F, Hogan TR, Tapsall JW, Goarant C.

Antimicrob Agents Chemother. 2009 Mar;53(3):1264-7. doi: 10.1128/AAC.01104-08. Epub 2009 Jan 5.

15.

Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.

Lo JY, Ho KM, Leung AO, Tiu FS, Tsang GK, Lo AC, Tapsall JW.

Antimicrob Agents Chemother. 2008 Oct;52(10):3564-7. doi: 10.1128/AAC.00198-08. Epub 2008 Jul 28.

16.

Exploring 'best practice' for nucleic acid detection of Neisseria gonorrhoeae.

Whiley DM, Garland SM, Harnett G, Lum G, Smith DW, Tabrizi SN, Sloots TP, Tapsall JW.

Sex Health. 2008 Mar;5(1):17-23. Review.

PMID:
18361850
17.

Analysis of trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Australia, 1997 2006.

Tapsall JW, Limnios EA, Murphy D; Australian Gonococcal Surveillance Programme.

J Antimicrob Chemother. 2008 Jan;61(1):150-5. Epub 2007 Nov 6.

PMID:
17986492
18.

Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone.

Whiley DM, Limnios EA, Ray S, Sloots TP, Tapsall JW.

Antimicrob Agents Chemother. 2007 Sep;51(9):3111-6. Epub 2007 Jun 25.

19.
20.

Increasing resistance to ciprofloxacin and other antibiotics in Neisseria gonorrhoeae from East Java and Papua, Indonesia, in 2004 - implications for treatment.

Sutrisna A, Soebjakto O, Wignall FS, Kaul S, Limnios EA, Ray S, Nguyen NL, Tapsall JW.

Int J STD AIDS. 2006 Dec;17(12):810-2.

PMID:
17212856
21.

Further questions regarding the role of mosaic penA sequences in conferring reduced susceptibility to ceftriaxone in Neisseria gonorrhoeae.

Whiley DM, Limnios EA, Ray S, Sloots TP, Tapsall JW.

Antimicrob Agents Chemother. 2007 Feb;51(2):802-3. Epub 2006 Nov 13. No abstract available.

22.

Supplemental testing is still required in australia for samples positive for Neisseria gonorrhoeae by nucleic acid detection tests.

Lum G, Garland SM, Tabrizi S, Harnett G, Smith DW, Sloots TP, Whiley DM, Tapsall JW.

J Clin Microbiol. 2006 Nov;44(11):4292-4; author reply 4293-4. No abstract available.

23.

Evidence that the gonococcal porA pseudogene is present in a broad range of Neisseria gonorrhoeae strains; suitability as a diagnostic target.

Whiley DM, Anderson TP, Barratt K, Beaman MH, Buda PJ, Carter M, Freeman K, Hallsworth P, Limnios EA, Lum G, Merien F, Vernel-Pauillac F, Tapsall JW, Witt MJ, Nissen MD, Sloots TP.

Pathology. 2006 Oct;38(5):445-8.

PMID:
17008285
26.

Nucleic acid amplification testing for Neisseria gonorrhoeae: an ongoing challenge.

Whiley DM, Tapsall JW, Sloots TP.

J Mol Diagn. 2006 Feb;8(1):3-15. Review.

27.

Probable transmission of meningococcal disease on a school bus.

Beard FH, McAnulty JM, Tapsall JW, Zaia AM.

Med J Aust. 2006 Jan 16;184(2):90. No abstract available.

PMID:
16411878
28.

What management is there for gonorrhea in the postquinolone era?

Tapsall JW.

Sex Transm Dis. 2006 Jan;33(1):8-10. No abstract available.

PMID:
16385215
29.

A cluster of culture positive gonococcal infections but with false negative cppB gene based PCR.

Lum G, Freeman K, Nguyen NL, Limnios EA, Tabrizi SN, Carter I, Chambers IW, Whiley DM, Sloots TP, Garland SM, Tapsall JW.

Sex Transm Infect. 2005 Oct;81(5):400-2.

30.

Molecular tests can allow confirmation of invasive meningococcal disease when isolates yield atypical maltose, glucose or gamma-glutamyl peptidase test results.

Zaia A, Griffith JM, Hogan TR, Tapsall JW, Bainbridge P, Neill R, Tribe D.

Pathology. 2005 Oct;37(5):378-9.

PMID:
16194849
31.
32.

Evaluation of the Australian Gonococcal Surveillance Programme.

Samaan G, Roche PW, Greig JE, Tapsall JW; Australian Gonococcal Surveillance Programme.

Commun Dis Intell Q Rep. 2005;29(2):143-9.

33.

Antibiotic resistance in Neisseria gonorrhoeae.

Tapsall JW.

Clin Infect Dis. 2005 Aug 15;41 Suppl 4:S263-8. Review.

PMID:
16032562
34.

In vitro assessment of the further potential for development of fluoroquinolone resistance in Neisseria meningitidis.

Shultz TR, White PA, Tapsall JW.

Antimicrob Agents Chemother. 2005 May;49(5):1753-60.

35.

Cryptic-plasmid-free gonococci may contribute to failure of cppB gene-based assays to confirm results of BD ProbeTEC PCR for identification of Neisseria gonorrhoeae.

Tapsall JW, Limnios EA, Nguyen NL, Carter I, Lum G, Freeman K, Tabrizi SN, Garland SM, Whiley DM, Sloots TP, Chambers IW.

J Clin Microbiol. 2005 Apr;43(4):2036-7. No abstract available.

36.

The antimicrobial resistance containment and surveillance approach--a public health tool.

Simonsen GS, Tapsall JW, Allegranzi B, Talbot EA, Lazzari S.

Bull World Health Organ. 2004 Dec;82(12):928-34. Epub 2005 Jan 5.

37.

Epidemiological characteristics and molecular basis of fluoroquinolone-resistant Neisseria gonorrhoeae strains isolated in Korea and nearby countries.

Yong D, Kim TS, Choi JR, Yum JH, Lee K, Chong Y, Oh HB, Shultz T, Tapsall JW.

J Antimicrob Chemother. 2004 Aug;54(2):451-5. Epub 2004 Jul 1.

PMID:
15231766
38.

Evaluation of real time polymerase chain reaction assays for confirmation of Neisseria gonorrhoeae in clinical samples tested positive in the Roche Cobas Amplicor assay.

Tabrizi SN, Chen S, Cohenford MA, Lentrichia BB, Coffman E, Shultz T, Tapsall JW, Garland SM.

Sex Transm Infect. 2004 Feb;80(1):68-71.

39.

Chloramphenicol-resistant Neisseria meningitidis containing catP isolated in Australia.

Shultz TR, Tapsall JW, White PA, Ryan CS, Lyras D, Rood JI, Binotto E, Richardson CJ.

J Antimicrob Chemother. 2003 Nov;52(5):856-9. Epub 2003 Oct 16.

PMID:
14563894
40.

Monitoring antimicrobial resistance for public health action.

Tapsall JW.

Commun Dis Intell Q Rep. 2003;27 Suppl:S70-4.

41.

Late-onset and recurrent neonatal Group B streptococcal disease associated with breast-milk transmission.

Kotiw M, Zhang GW, Daggard G, Reiss-Levy E, Tapsall JW, Numa A.

Pediatr Dev Pathol. 2003 May-Jun;6(3):251-6. Epub 2003 Apr 14.

PMID:
12687430
42.
43.

Refining the public health response to primary meningococcal conjunctivitis.

Poulos RG, Smedley EJ, Ferson MJ, Bolisetty S, Tapsall JW.

Commun Dis Intell Q Rep. 2002;26(4):592-5.

44.
45.

Surveillance of antibiotic resistance in invasive isolates of Neisseria meningitidis in Australia 1994-1999.

Tapsall JW, Shultz T, Limnios E, Munro R, Mercer J, Porritt R, Griffith J, Hogg G, Lum G, Lawrence A, Hansman D, Collignon P, Southwell P, Ott K, Gardam M, Richardson CJ, Bates J, Murphy D, Smith H; National Neisseria Network of Australia.

Pathology. 2001 Aug;33(3):359-61.

PMID:
11523940
46.

The antibiotic susceptibility of Neisseria gonorrhoeae isolated in Ulaanbaatar, Mongolia.

Lkhamsuren E, Shultz TR, Limnios EA, Tapsall JW.

Sex Transm Infect. 2001 Jun;77(3):218-9. No abstract available.

47.

Characteristics of homosexually-active men with gonorrhoea during an epidemic in Sydney, Australia.

Donovan B, Bodsworth NJ, Rohrsheim R, McNulty A, Tapsall JW.

Int J STD AIDS. 2001 Jul;12(7):437-43.

PMID:
11394979
49.

Toxicities of flucloxacillin and dicloxacillin--is there really a difference?

Gosbell IB, Turnidge JD, Tapsall JW, Benn RA.

Med J Aust. 2000 Nov 6;173(9):500-1. No abstract available.

PMID:
11149309
50.

Increasing gonorrhoea reports--not only in London.

Donovan B, Bodsworth NJ, Rohrsheim R, McNulty A, Tapsall JW.

Lancet. 2000 May 27;355(9218):1908. No abstract available.

PMID:
10866463

Supplemental Content

Loading ...
Support Center